Remus Pharmaceuticals Announces Strong Financial Results and Strategic Growth in FY26

Remus Pharmaceuticals Announces Strong Financial Results and Strategic Growth in FY26​

Remus Pharmaceuticals Limited announced its audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026. The company highlighted significant year-over-year growth and aggressive expansion across global markets in its latest update.

Financial Performance Review​

The financial results show robust growth across key metrics for the full fiscal year (FY26) and the second half (H2 FY26).

The consolidated performance comparison highlights the following figures:


Comparing the half-year results further details the strong performance period:


For the second half of the fiscal year (H2 FY26) compared to the previous year (H2 FY25), the growth rates were:

Key Business Highlights and Expansion​

The company detailed its operational achievements, focusing on product expansion and market penetration.

Product and Portfolio Strengthening:
Remus strengthened its product portfolio through key developments:

• The company in-licensed Rifaximin (200 mg & 550 mg) and Fexofenadine 180 mg for critical markets, including Mexico, Chile, Vietnam, and Peru. These licenses are supported by bioequivalence (BE) studies, strengthening the anti-infective and anti-allergy segment.
• A direct government tender for Ceftazidime + Avibactam 2.5 g Injection was secured in Nicaragua, complemented by ongoing regulatory filings in several international markets.
• To capitalize on the growth of the GLP-1 and anti-obesity segment, filings for Semaglutide tablets and injections were initiated across non-patented emerging markets through both B2B and B2C channels.
• The CNS portfolio expanded with supply orders for Rivastigmine Patch in Venezuela, accompanied by filings in Venezuela and other markets.
• The oncology pipeline was bolstered by in-licensing Peg-filgrastim and Filgrastim PFS injections for the Philippines and Vietnam, with regulatory submissions planned shortly.
• The institutional presence in Saudi Arabia was reinforced after being awarded the NUPCO tender for Topiramate capsules in February 2026.
• The company expanded its Urology portfolio with the launch of Mirabegron 25 mg XR in Venezuela, Ecuador, and Bolivia, alongside Mirabegron + Solifenacin in Ecuador.

Market and Geographic Expansion:
Through a dedicated geographic expansion strategy, Remus broadened its commercial presence into four new markets: Myanmar, Nicaragua, North Macedonia, and Madagascar.

• The company successfully cleared the Peru DIGEMID audit in February 2026, boosting its regulatory standing and fueling further expansion across Peru and the broader Latin American region, with plans to file over 50 new registrations in the next four months.
• Five products were filed to ISP Chile, and the company in-licensed Dapagliflozin 10 mg tablets and Rivaroxaban 3 SKUs with Bioequivalence studies for the Chilean market.
• In Bolivia, under the brand Relius, 26 products were launched through the B2C segment, with 40 additional launches planned over the next six months. The specialty injection portfolio was further strengthened by the registration of Triptorelin Injection 11.25 mg in Bolivia.
• The CNS portfolio was launched in Relius Bolivia through D2C channels, featuring products such as Brivaracetam, Valproic Acid, Risperidone, and Lamotrigine tablets.

Management Commentary​

Mr. Arpit Deepakkumar Shah, Managing Director of Remus Pharmaceuticals Limited, commented on the results, stating that the financial performance for FY 2026 reflects the team's resilience, operational discipline, and focus on creating value.

He noted that the success was achieved despite complex macroeconomic conditions. He highlighted that the strong growth of the B2C entity, Relius, was a major driver, validating the strategic decision to enter pharmacies directly to leverage higher-margin products.

Looking ahead to FY 2027, the company plans to accelerate its expansion, stating a commitment to pursuing disciplined, profitable growth to generate sustainable, long-term value for stakeholders.

Disclaimer: Results for the second half and financial year ended March 31, 2026, prepared under Ind AS, are available on the company's website.

REMUS Stock Price Movement​

Today, Remus Pharmaceuticals Limited shares shed 4.03% to close at ₹846.10. The stock saw considerable trading activity, with a total volume of 40,300 shares recorded during the session.